Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Other Accumulated Expenses (2021 - 2025)

Aligos Therapeutics (ALGS) has disclosed Other Accumulated Expenses for 5 consecutive years, with $3.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Accumulated Expenses rose 27.41% year-over-year to $3.5 million, compared with a TTM value of $3.5 million through Sep 2025, up 27.41%, and an annual FY2024 reading of $2.7 million, down 59.75% over the prior year.
  • Other Accumulated Expenses was $3.5 million for Q3 2025 at Aligos Therapeutics, up from $2.5 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $6.6 million in Q4 2023 and bottomed at $483000.0 in Q2 2021.
  • Average Other Accumulated Expenses over 5 years is $2.0 million, with a median of $1.5 million recorded in 2022.
  • The sharpest move saw Other Accumulated Expenses surged 350.31% in 2023, then plummeted 59.75% in 2024.
  • Year by year, Other Accumulated Expenses stood at $1.2 million in 2021, then increased by 19.27% to $1.5 million in 2022, then skyrocketed by 350.31% to $6.6 million in 2023, then crashed by 59.75% to $2.7 million in 2024, then soared by 31.09% to $3.5 million in 2025.
  • Business Quant data shows Other Accumulated Expenses for ALGS at $3.5 million in Q3 2025, $2.5 million in Q1 2025, and $2.7 million in Q4 2024.